In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the shares following quarterly results. Though Biogen has ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...